Globeflex Capital L P Sells 3,661 Shares of United Therapeutics Corporation $UTHR

Globeflex Capital L P lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 20.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,917 shares of the biotechnology company’s stock after selling 3,661 shares during the period. United Therapeutics makes up 1.0% of Globeflex Capital L P’s portfolio, making the stock its 23rd biggest position. Globeflex Capital L P’s holdings in United Therapeutics were worth $6,781,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Darwin Global Management Ltd. bought a new stake in United Therapeutics in the 3rd quarter valued at approximately $317,617,000. Norges Bank bought a new stake in United Therapeutics in the 4th quarter valued at approximately $293,418,000. Baillie Gifford & Co. bought a new stake in United Therapeutics in the 4th quarter valued at approximately $157,390,000. Balyasny Asset Management L.P. lifted its stake in United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after acquiring an additional 136,883 shares in the last quarter. Finally, Sofinnova Investments Inc. bought a new stake in United Therapeutics in the 2nd quarter valued at approximately $34,055,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.3%

NASDAQ:UTHR opened at $547.69 on Friday. The firm has a market capitalization of $23.25 billion, a price-to-earnings ratio of 20.22, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock’s 50 day moving average price is $568.06 and its two-hundred day moving average price is $518.61.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm earned $6.63 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the topic of several research reports. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 614,043 shares of company stock worth $346,186,880. 8.60% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.